Pharmacokinetics and pharmacodynamics of direct oral anticoagulants

References

• Chen A, Stecker E, Warden BA. Direct oral anticoagulant use: a practical guide to common clinical challenges. J Am Heart Assoc. 2020;9. doi: 10.1161/JAHA.120.017559
   Web of Science ®Google Scholar
• DeHaas KA. The direct oral anticoagulants apixaban, rivaroxaban, and edoxaban. AmSoci Clin Lab Sci. 2017;30:2–6. doi: 10.29074/ascls.30.1.2
   Google Scholar
• Byon W, Garonzik S, Boyd RA, et al. Apixaban: a clinical pharmacokinetic and pharmacodynamic review. Clin Pharmacokinet. 2019;58(10):1265–1279. doi: 10.1007/s40262-019-00775-z
   PubMed Web of Science ®Google Scholar
• Bonar R, Favaloro EJ, Mohammed S, et al. The effect of the direct factor Xa inhibitors apixaban and rivaroxaban on haemostasis tests: a comprehensive assessment using in vitro and ex vivo samples. Pathology. 2016;48(1):60–71. doi: 10.1016/j.pathol.2015.11.025
   PubMed Web of Science ®Google Scholar
• Bounameaux H, Camm AJ. Edoxaban: an update on the new oral direct factor Xa inhibitor. Drugs. 2014;74(11):1209–1231. doi: 10.1007/s40265-014-0261-1
   PubMed Web of Science ®Google Scholar
• Parasrampuria DA, Truitt KE. Pharmacokinetics and pharmacodynamics of edoxaban, a non-vitamin K antagonist oral anticoagulant that inhibits clotting factor Xa. Clin Pharmacokinet. 2016;55(6):641–655. doi: 10.1007/s40262-015-0342-7
   PubMed Web of Science ®Google Scholar
• Mueck W, Stampfuss J, Kubitza D, et al. Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban. Clin Pharmacokinet. 2014;53(1):1–16. doi: 10.1007/s40262-013-0100-7
   PubMed Web of Science ®Google Scholar
• Graff J, von Hentig N, Misselwitz F, et al. Effects of the oral, direct factor Xa inhibitor rivaroxaban on platelet-induced thrombin generation and prothrombinase activity 1. J Clin Pharmacol. 2007;47(11):1398–1407. doi: 10.1177/0091270007302952
   PubMed Web of Science ®Google Scholar
• Stangier J, Stähle H, Rathgen K, et al. Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Clin Pharmacokinet. 2008;47(1):47–59. doi: 10.2165/00003088-200847010-00005
   PubMed Web of Science ®Google Scholar
• Electronic Medicines Compendium. Pradaxa 150mg hard capsules [Internet]. 2022 [cited 2023 Jan 27]. Available from: https://www.medicines.org.uk/emc/product/4703/smpc.
   Google Scholar
• Eisert WG, Hauel N, Stangier J, et al. Dabigatran: an oral novel potent reversible nonpeptide inhibitor of thrombin. Arterioscler Thromb Vasc Biol. 2010;30(10):1885–1889. doi: 10.1161/ATVBAHA.110.203604
   PubMed Web of Science ®Google Scholar
• Mainbourg S, Cucherat M, Provencher S, et al. Twice- or once-daily dosing of direct oral anticoagulants, a systematic review and meta-analysis. Thromb Res. 2021 [cited 2023 Sep 12];197:24–32.
   PubMed Web of Science ®Google Scholar
• Jakowenko N, Nguyen S, Ruegger M, et al. Apixaban and rivaroxaban anti-Xa level utilization and associated bleeding events within an academic health system. Thromb Res. 2020;196:276–282. doi: 10.1016/j.thromres.2020.09.002
   PubMed Web of Science ®Google Scholar
• Rose DZ, Chang JY, Yi X, et al. Direct oral anticoagulant failures in atrial fibrillation with stroke: retrospective admission analysis and novel classification system. Neurohospitalist. 2023;13(3):256–265. doi: 10.1177/19418744231161390
   PubMed Web of Science ®Google Scholar
• Rose DZ, Burgin WS. Direct oral anticoagulant failure in stroke/transient ischaemic attack: neurologic and pharmacokinetic considerations. Eur Heart J Case Rep. 2020 [cited 2023 Sep 12];4:1–2. doi: 10.1093/ehjcr/ytaa178
   PubMedGoogle Scholar
• Steffel J, Verhamme P, Potpara TS, et al. The 2018 European Heart rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J. 2018;39(16):1330–1393. doi: 10.1093/eurheartj/ehy136
   PubMed Web of Science ®Google Scholar
• Margetić S, C¨elap I, Huzjan AL, et al. DOAC dipstick testing can reliably exclude the presence of clinically relevant DOAC concentrations in Circulation. Thromb Haemost. 2022 [cited 2023 May 23];122:1542–1548. doi: 10.1055/a-1753-2748
   PubMed Web of Science ®Google Scholar
• Merrelaar AE, Bögl MS, Buchtele N, et al. Performance of a qualitative point-of-care strip test to detect DOAC exposure at the emergency department: a cohort-type cross-sectional diagnostic accuracy study. Thromb Haemost. 2022 [cited 2023 May 23];122(10):1723–1731. doi: 10.1055/s-0042-1750327
   PubMed Web of Science ®Google Scholar
• Willekens G, Studt J, Mendez A, et al. A universal anti‐Xa assay for rivaroxaban, apixaban, and edoxaban measurements: method validation, diagnostic accuracy and external validation. Br J Haematol. 2021;193(6):1203–1212. doi: 10.1111/bjh.17470
   PubMed Web of Science ®Google Scholar
• Samama M, Contant G, Spiro TE, et al. Laboratory assessment of rivaroxaban: a review. Thromb J. 2013;11(1):11. doi: 10.1186/1477-9560-11-11
   PubMedGoogle Scholar
• Foulon-Pinto G, Lafuente C, Jourdi G, et al. Assessment of DOAC in GEriatrics (adage study): Rivaroxaban/apixaban concentrations and thrombin generation profiles in NVAF very elderly patients. Thromb Haemost. 2023 [cited 2023 May 23];123(4):402–414. doi: 10.1055/a-1981-1763
   PubMedGoogle Scholar
• Douxfils J, Adcock DM, Bates SM, et al. 2021 update of the International council for standardization in haematology recommendations for laboratory measurement of direct oral anticoagulants. Thromb Haemost. 2021;121(08):1008–1020. doi: 10.1055/a-1450-8178
   PubMed Web of Science ®Google Scholar
• Wang X, Mondal S, Wang J, et al. Effect of activated charcoal on apixaban pharmacokinetics in healthy subjects. Am J Cardiovasc Drugs. 2014;14(2):147–154. doi: 10.1007/s40256-013-0055-y
   PubMed Web of Science ®Google Scholar
• Daiichi Sankyo Europe GmbH. Lixiana summary of product characteristics [Internet]. 2020 [cited 2022 Dec 23]. Available from: https://www.ema.europa.eu/en/documents/product-information/lixiana-epar-product-information_en.pdf.
   Google Scholar
• Electronic Medicines Compendium. Lixiana 60mg film-coated tablets [Internet]. 2022 [cited 2022 Dec 23]. Available from: https://www.medicines.org.uk/emc/product/6905/smpc#gref.
   Google Scholar
• Ollier E, Hodin S, Lanoiselée J, et al. Effect of activated charcoal on rivaroxaban complex absorption. Clin Pharmacokinet. 2017;56(7):793–801. doi: 10.1007/s40262-016-0485-1
   PubMed Web of Science ®Google Scholar
• Alikhan R, Rayment R, Keeling D, et al. The acute management of haemorrhage, surgery and overdose in patients receiving dabigatran. Emer Med J. 2014;31(2):163–168. doi: 10.1136/emermed-2012-201976
   PubMed Web of Science ®Google Scholar
• Boehringer Ingelheim Pharmaceuticals Inc. Pradaxa prescribing infomation [Internet]. 2011 [cited 2023 Jan 27]. Ava: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022512s007lbl.pdf.
   Google Scholar
• Boehringer Ingelheim International GmbH. Pradaxa summary of product characteristics [Internet]. 2018 [cited 2023 Jan 27]. Available from: https://www.ema.europa.eu/en/documents/product-information/pradaxa-epar-product-information_en.pdf.
   Google Scholar
• Electronic Medicines Compendium. Ondexxya 200 mg powder for solution for infusion [Internet]. 2022 [cited 2022 Dec 12]. Available from: https://www.medicines.org.uk/emc/product/10933/smpc.
   Google Scholar
• Electronic Medicines Compendium. Praxbind 2.5 g/50 mL solution for injection/infusion [Internet]. 2022 [cited 2023 Feb 3]. Available from: https://www.medicines.org.uk/emc/product/5073.
   Google Scholar
• Alexion Europe SAS. Ondexxya summary of product characterisitcs [Internet]. 2021 [cited 2023 Feb 10]. Available from: https://www.ema.europa.eu/en/documents/product-information/ondexxya-epar-product-information_en.pdf.
   Google Scholar
• Alexion Pharmaceuticals Inc. Andexxa prescribing information [Internet]. 2022 [cited 2023 Feb 10]. Available from: https://www.fda.gov/media/113279/download.
   Google Scholar
• Benz AP, Xu L, Eikelboom JW, et al. Andexanet alfa for specific anticoagulation reversal in patients with acute bleeding during treatment with edoxaban. Thromb Haemost. 2022;122:998–1005.
   PubMed Web of Science ®Google Scholar
• National Institute of Health. Trial of andexanet alfa in ICH patients receiving an oral FXa inhibitor [Internet]. 2023 [cited 2023 Feb 10]. Available from: https://clinicaltrials.gov/ct2/show/NCT03661528.
   Google Scholar
• Müller M, Eastline J, Nagler M, et al. Application of prothrombin complex concentrate for reversal of direct oral anticoagulants in clinical practice: indications, patient characteristics and clinical outcomes compared to reversal of vitamin K antagonists. Scand J Trauma Resusc Emerg Med. 2019 [cited 2023 Sep 12];27. PMC6480883/. doi: 10.1186/s13049-019-0625-3
   Web of Science ®Google Scholar
• Amin S, Kasischke KA, Elsayed K, et al. No time to lose: cases of anticoagulant reversal before Thrombolysis in acute ischemic stroke patients. Cureus. 2022 [cited 2023 Sep 12];14. doi: 10.7759/cureus.21406
   Web of Science ®Google Scholar
• Byon W, Nepal S, Schuster AE, et al. Regional gastrointestinal absorption of apixaban in healthy subjects. J Clin Pharmacol. 2018;58(7):965–971. doi: 10.1002/jcph.1097
   PubMed Web of Science ®Google Scholar
• Vakkalagadda B, Frost C, Byon W, et al. Effect of rifampin on the pharmacokinetics of apixaban, an oral direct inhibitor of factor Xa. Am J Cardiovasc Drugs. 2016;16(2):119–127. doi: 10.1007/s40256-015-0157-9
   PubMed Web of Science ®Google Scholar
• Song Y, Chang M, Suzuki A, et al. Evaluation of crushed tablet for oral administration and the Effect of food on apixaban pharmacokinetics in healthy adults. Clin Ther. 2016;38(7):1674–1685.e1. doi: 10.1016/j.clinthera.2016.05.004
   PubMed Web of Science ®Google Scholar
• Frost C, Wang J, Nepal S, et al. Apixaban, an oral, direct factor X a inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects. Br J Clin Pharmacol. 2013;75:476–487.
   PubMed Web of Science ®Google Scholar
• Electronic Medicines Compendium. Eliquis 5 mg film-coated tablets [Internet]. 2022 [cited 2022 Dec 12]. Available from: https://www.medicines.org.uk/emc/product/2878/smpc.
   Google Scholar
• Bristol-Myers Squibb/Pfizer EEIG. Eliquis summary of product characteristics [Internet]. 2021 [cited 2022 Dec 23]. Available from: https://www.ema.europa.eu/en/documents/product-information/eliquis-epar-product-information_en.pdf.
   Google Scholar
• Bristol-Myers Squibb Company PI. Eliquis (apixaban) prescribing information. [Internet]. 2021 [cited 2022 Dec 12]. Available from: https://packageinserts.bms.com/pi/pi_eliquis.pdf.
   Google Scholar
• Frost C, Nepal S, Wang J, et al. Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor X a inhibitor, in healthy subjects. Br J Clin Pharmacol. 2013;76:776–786.
   PubMed Web of Science ®Google Scholar
• Song Y, Wang X, Perlstein I, et al. Relative bioavailability of apixaban solution or crushed tablet formulations administered by mouth or nasogastric tube in healthy subjects. Clin Ther. 2015;37(8):1703–1712. doi: 10.1016/j.clinthera.2015.05.497
   PubMed Web of Science ®Google Scholar
• Upreti VV, Wang J, Barrett YC, et al. Effect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjects. Br J Clin Pharmacol. 2013;76:908–916. doi: 10.1111/bcp.12114
   PubMed Web of Science ®Google Scholar
• Choi Y, Kushnir M, Billett HH. Apixaban is safe and effective in morbidly obese patients: a retrospective analysis of 390 patients with BMI ≥40. Blood. 2017;130:1105. doi: 10.1182/blood.V130.Suppl_1.1105.1105
   Web of Science ®Google Scholar
• Cohen A, Sah J, Lee T, et al. Effectiveness and safety of apixaban vs. Warfarin in venous thromboembolism patients with obesity and morbid obesity. J Clin Med. 2021;10(2):200. doi: 10.3390/jcm10020200
   PubMed Web of Science ®Google Scholar
• Cohen AT, Pan S, Byon W, et al. Efficacy, safety, and exposure of apixaban in patients with high body weight or obesity and venous thromboembolism: insights from AMPLIFY. Adv Ther. 2021;38(6):3003–3018. doi: 10.1007/s12325-021-01716-8
   PubMed Web of Science ®Google Scholar
• O’Kane CP, Avalon JCO, Lacoste JL, et al. Apixaban and rivaroxaban use for atrial fibrillation in patients with obesity and BMI ≥50 kg/m 2. Pharmacother J Human Pharmacol Drug Ther. 2022;42(2):112–118. doi: 10.1002/phar.2651
   Google Scholar
• Ballerie A, Nguyen Van R, Lacut K, et al. Apixaban and rivaroxaban in obese patients treated for venous thromboembolism: drug levels and clinical outcomes. Thromb Res. 2021;208:39–44. doi: 10.1016/j.thromres.2021.10.009
   PubMed Web of Science ®Google Scholar
• Jamieson MJ, Byon W, Dettloff RW, et al. Apixaban use in obese patients: a review of the pharmacokinetic, Interventional, and observational study data. Am J Cardiovasc Drugs. 2022;22(6):615–631. doi: 10.1007/s40256-022-00524-x
   PubMed Web of Science ®Google Scholar
• He K, Luettgen JM, Zhang D, et al. Preclinical pharmacokinetics and pharmacodynamics of apixaban, a potent and selective factor Xa inhibitor. Eur J Drug Metab Pharmacokinet. 2011;36(3):129–139. doi: 10.1007/s13318-011-0037-x
   PubMed Web of Science ®Google Scholar
• Frost CE, Song Y, Shenker A, et al. Effects of age and sex on the single-dose pharmacokinetics and pharmacodynamics of apixaban. Clin Pharmacokinet. 2015;54(6):651–662. doi: 10.1007/s40262-014-0228-0
   PubMed Web of Science ®Google Scholar
• Cirincione B, Kowalski K, Nielsen J, et al. Population pharmacokinetics of apixaban in subjects with nonvalvular atrial fibrillation. CPT Pharmacometrics Syst Pharmacol. 2018;7(11):728–738. doi: 10.1002/psp4.12347
   PubMedGoogle Scholar
• Wang L, Zhang D, Raghavan N, et al. In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies. Drug Metab Dispos. 2010;38(3):448–458. doi: 10.1124/dmd.109.029694
   PubMed Web of Science ®Google Scholar
• Zhang D, He K, Herbst JJ, et al. Characterization of Efflux Transporters involved in distribution and disposition of apixaban. Drug Metab Dispos. 2013;41(4):827–835. doi: 10.1124/dmd.112.050260
   PubMed Web of Science ®Google Scholar
• Fernandez S, Lenoir C, Samer C, et al. Drug interactions with apixaban: a systematic review of the literature and an analysis of VigiBase, the World Health Organization database of spontaneous safety reports. Pharmacol Res Perspect. 2020;8(5):8. doi: 10.1002/prp2.647
   Web of Science ®Google Scholar
• Candeloro M, Eikelboom JW, Chan N, et al. Carbamazepine, phenytoin, and oral anticoagulants: drug‐drug interaction and clinical events in a retrospective cohort. Res Pract Thromb Haemost. 2022;6(2):6. doi: 10.1002/rth2.12650
   Web of Science ®Google Scholar
• Shurrab M, Jackevicius CA, Austin PC, et al. Association between concurrent use of amiodarone and DOACs and risk of bleeding in patients with atrial fibrillation. Am J Cardiol. 2023 [cited 2023 Sep 12];186:58–65.
   PubMed Web of Science ®Google Scholar
• Lin SY, Bin LY, Ho LT, et al. Impact of amiodarone on plasma concentration of direct oral anticoagulant in patients with atrial fibrillation. J Formos Med Assoc. 2023 [cited 2023 Sep 12];122(8):776–784. doi: 10.1016/j.jfma.2023.02.012
   PubMedGoogle Scholar
• U.S. Food and Drug Administration. FDA’s Examples of Drugs that Interact with CYP Enzymes and Transporter Systems. 2023.
   Google Scholar
• Raghavan N, Frost CE, Yu Z, et al. Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab Dispos. 2009;37(1):74–81. doi: 10.1124/dmd.108.023143
   PubMed Web of Science ®Google Scholar
• Fawzy AM, Lip GYH. Pharmacokinetics and pharmacodynamics of oral anticoagulants used in atrial fibrillation. Expert Opin Drug Metab Toxicol. 2019;15(5):381–398. doi: 10.1080/17425255.2019.1604686
   PubMed Web of Science ®Google Scholar
• Chang M, Yu Z, Shenker A, et al. Effect of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of apixaban. J Clin Pharmacol. 2016;56(5):637–645. doi: 10.1002/jcph.633
   PubMed Web of Science ®Google Scholar
• Byon W, Sweeney K, Frost C, et al. Population pharmacokinetics, pharmacodynamics, and exploratory exposure-response analyses of apixaban in subjects treated for venous thromboembolism. CPT Pharmacometrics Syst Pharmacol. 2017;6:340–349. doi: 10.1002/psp4.12184
   PubMedGoogle Scholar
• Siontis KC, Zhang X, Eckard A, et al. Outcomes associated with apixaban use in patients with end-stage kidney disease and atrial fibrillation in the United States. Circulation. 2018;138(15):1519–1529. doi: 10.1161/CIRCULATIONAHA.118.035418
   PubMed Web of Science ®Google Scholar
• Stanifer JW, Pokorney SD, Chertow GM, et al. Apixaban versus warfarin in patients with atrial fibrillation and advanced chronic kidney disease. Circulation. 2020;141(17):1384–1392. doi: 10.1161/CIRCULATIONAHA.119.044059
   PubMed Web of Science ®Google Scholar
• Chen C, Cao Y, Zheng Y, et al. Effect of rivaroxaban or apixaban in atrial fibrillation patients with stage 4–5 chronic kidney disease or on dialysis. Cardiovasc Drugs Ther. 2021;35(2):273–281. doi: 10.1007/s10557-021-07144-8
   PubMed Web of Science ®Google Scholar
• Cohen AT, Sah J, Dhamane AD, et al. Effectiveness and safety of apixaban versus warfarin in venous thromboembolism patients with chronic kidney disease. Thromb Haemost. 2022;122(6):926–938. doi: 10.1055/s-0041-1740254
   PubMedGoogle Scholar
• Gurevitz C, Giladi E, Barsheshet A, et al. Comparison of low and Full dose apixaban versus warfarin in patients with atrial fibrillation and renal dysfunction (from a national registry). Am J Cardiol. 2021;159:87–93. doi: 10.1016/j.amjcard.2021.08.022
   PubMed Web of Science ®Google Scholar
• Knueppel P, Bang SH, Troyer C, et al. Evaluation of standard versus reduced dose apixaban for the treatment of venous thromboembolism in patients with severe renal disease (ESRD-VTE). Thromb Res. 2022;220:91–96. doi: 10.1016/j.thromres.2022.10.014
   PubMed Web of Science ®Google Scholar
• Harrington J, Carnicelli AP, Hua K, et al. Direct oral anticoagulants versus warfarin across the spectrum of kidney function: patient-level network meta-analyses from COMBINE AF. Circulation. 2023 [cited 2023 Sep 12];147(23):1748–1757. doi: 10.1161/CIRCULATIONAHA.122.062752
   PubMed Web of Science ®Google Scholar
• Parasrampuria DA, Kanamaru T, Connor A, et al. Evaluation of regional gastrointestinal absorption of edoxaban using the enterion capsule. J Clin Pharmacol. 2015;55(11):1286–1292. doi: 10.1002/jcph.540
   PubMed Web of Science ®Google Scholar
• Yin OQP, Tetsuya K, Miller R. Edoxaban population pharmacokinetics and exposure–response analysis in patients with non-valvular atrial fibrillation. Eur J Clin Pharmacol. 2014;70(11):1339–1351. doi: 10.1007/s00228-014-1736-4
   PubMed Web of Science ®Google Scholar
• Matsushima N, Lee F, Sato T, et al. Bioavailability and safety of the factor Xa inhibitor edoxaban and the effects of quinidine in healthy subjects. Clin Pharmacol Drug Dev. 2013;2(4):358–366. doi: 10.1002/cpdd.53
   PubMed Web of Science ®Google Scholar
• Liu L, Li X, Liu Y, et al. Bioequivalence and pharmacokinetic study of 2 edoxaban tablets in healthy Chinese subjects. Clin Pharmacol Drug Dev. 2022;11(12):1440–1446. doi: 10.1002/cpdd.1156
   PubMed Web of Science ®Google Scholar
• Mendell J, Tachibana M, Shi M, et al. Effects of food on the pharmacokinetics of edoxaban, an oral direct factor Xa inhibitor, in healthy volunteers. J Clin Pharmacol. 2011;51(5):687–694. doi: 10.1177/0091270010370974
   PubMed Web of Science ®Google Scholar
• Daiichi Sankyo Co. L. Edoxaban (Savaysa) prescribing information [Internet]. 2015 [cited 2022 Dec 23]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206316lbl.pdf.
   Google Scholar
• Duchin K, Duggal A, Atiee GJ, et al. An open-label crossover study of the pharmacokinetics of the 60-mg edoxaban tablet crushed and administered either by a nasogastric tube or in apple puree in healthy adults. Clin Pharmacokinet. 2018;57(2):221–228. doi: 10.1007/s40262-017-0554-0
   PubMed Web of Science ®Google Scholar
• Moll S, Crona DJ, Martin K. Direct oral anticoagulants in extremely obese patients: OK to use? Res Pract Thromb Haemost. 2019;3(2):152–155. doi: 10.1002/rth2.12178
   PubMed Web of Science ®Google Scholar
• Yin OQP, Miller R. Population pharmacokinetics and dose–exposure proportionality of edoxaban in healthy volunteers. Clin Drug Investig. 2014;34(10):743–752. doi: 10.1007/s40261-014-0229-7
   PubMed Web of Science ®Google Scholar
• Martin KA, Beyer‐Westendorf J, Davidson BL, et al. Use of direct oral anticoagulants in patients with obesity for treatment and prevention of venous thromboembolism: updated communication from the ISTH SSC subcommittee on control of anticoagulation. J Thromb Haemost. 2021;19(8):1874–1882. doi: 10.1111/jth.15358
   PubMed Web of Science ®Google Scholar
• Boriani G, Ruff CT, Kuder JF, et al. Edoxaban versus warfarin in patients with atrial fibrillation at the extremes of body weight: an analysis from the ENGAGE AF-TIMI 48 trial. Thromb Haemost. 2021;121(2):140–149. doi: 10.1055/s-0040-1716540
   PubMedGoogle Scholar
• Krekels EHJ, Niebecker R, Karlsson MO, et al. Population pharmacokinetics of edoxaban in patients with non-valvular atrial fibrillation in the ENGAGE AF-TIMI 48 study, a phase III clinical trial. Clin Pharmacokinet. 2016;55(9):1079–1090. doi: 10.1007/s40262-016-0378-3
   PubMed Web of Science ®Google Scholar
• Bathala MS, Masumoto H, Oguma T, et al. Pharmacokinetics, biotransformation, and mass balance of edoxaban, a selective, direct factor Xa inhibitor, in Humans. Drug Metab Dispos. 2012;40(12):2250–2255. doi: 10.1124/dmd.112.046888
   PubMed Web of Science ®Google Scholar
• Mikkaichi T, Yoshigae Y, Masumoto H, et al. Edoxaban Transport via P-Glycoprotein is a key factor for the drug’s disposition. Drug Metab Dispos. 2014;42(4):520–528. doi: 10.1124/dmd.113.054866
   PubMed Web of Science ®Google Scholar
• Mendell J, Johnson L, Chen S. An open-label, phase 1 study to evaluate the effects of hepatic impairment on edoxaban pharmacokinetics and pharmacodynamics. J Clin Pharmacol. 2015;55(12):1395–1405. doi: 10.1002/jcph.550
   PubMed Web of Science ®Google Scholar
• Jönsson S, Simonsson USH, Miller R, et al. Population pharmacokinetics of edoxaban and its main metabolite in a dedicated renal impairment study. J Clin Pharmacol. 2015;55(11):1268–1279. doi: 10.1002/jcph.541
   PubMed Web of Science ®Google Scholar
• Shimizu T, Tachibana M, Kimura T, et al. Population pharmacokinetics of edoxaban in Japanese atrial fibrillation patients with severe renal impairment. Clin Pharmacol Drug Dev. 2017;6(5):484–491. doi: 10.1002/cpdd.329
   PubMed Web of Science ®Google Scholar
• Lip GYH, Agnelli G. Edoxaban: a focused review of its clinical pharmacology. Eur Heart J. 2014;35(28):1844–1855. doi: 10.1093/eurheartj/ehu181
   PubMed Web of Science ®Google Scholar
• Ono R, Nishimura K, Takahashi H, et al. Impact of renal function on anti-factor Xa activity concentrations with edoxaban use in patients with non-valvular atrial fibrillation. Drugs R D. 2022;22(4):281–288. doi: 10.1007/s40268-022-00403-5
   PubMed Web of Science ®Google Scholar
• Yu HT, Yang P-S, Kim T-H, et al. Impact of renal function on outcomes with edoxaban in real-world patients with atrial fibrillation. Stroke. 2018;49(10):2421–2429. doi: 10.1161/STROKEAHA.118.021387
   PubMed Web of Science ®Google Scholar
• Fazio G, Dentamaro I, Gambacurta R, et al. Safety of edoxaban 30 mg in elderly patients with severe renal impairment. Clin Drug Investig. 2018;38(11):1023–1030. doi: 10.1007/s40261-018-0693-6
   PubMed Web of Science ®Google Scholar
• Buller HR, Decousus H, Grosso MA, et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 2013;369:1406–1415.
   PubMed Web of Science ®Google Scholar
• Bohula EA, Giugliano RP, Ruff CT, et al. Impact of renal function on outcomes with edoxaban in the ENGAGE AF-TIMI 48 trial. Circulation. 2016;134(1):24–36. doi: 10.1161/CIRCULATIONAHA.116.022361
   PubMed Web of Science ®Google Scholar
• Hakeam HA, Al-Sanea N. Effect of major gastrointestinal tract surgery on the absorption and efficacy of direct acting oral anticoagulants (DOACs). J Thromb Thrombolysis. 2017;43(3):343–351. doi: 10.1007/s11239-016-1465-x
   PubMed Web of Science ®Google Scholar
• Bratsos S. Pharmacokinetic properties of rivaroxaban in healthy human subjects. Cureus. 2019. doi: 10.7759/cureus.5484
   Web of Science ®Google Scholar
• Stampfuss J, Kubitza D, Becka M, et al. The effect of food on the absorption and pharmacokinetics of rivaroxaban. Int J Clin Pharmacol Ther. 2013;51(7):549–561. doi: 10.5414/CP201812
   PubMed Web of Science ®Google Scholar
• Janssen Pharmaceuticals. XARELTO (rivaroxaban) [Internet]. 2014 [cited 2023 Jan 13]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022406s015lbl.pdf.
   Google Scholar
• Electronic Medicines Compendium. Xarelto 15mg & 20mg film-coated tablets treatment initiation pack [Internet]. 2022 [cited 2023 Jan 13]. Available from: https://www.medicines.org.uk/emc/product/8419/smpc#gref.
   Google Scholar
• Electronic Medicines Compendium. Xarelto 10 mg film-coated tablets [Internet]. 2022 [cited 2023 Jan 13]. Available from: https://www.medicines.org.uk/emc/product/6402/smpc.
   Google Scholar
• Bayer AG Xarelto summary of product characteristics. 2018 [cited 2023 Jan 13]. Available from: https://www.ema.europa.eu/en/documents/product-information/xarelto-epar-product-information_en.pdf.
   Google Scholar
• Moore KT, Krook MA, Vaidyanathan S, et al. Rivaroxaban crushed tablet suspension characteristics and relative bioavailability in healthy adults when administered orally or via nasogastric tube. Clin Pharmacol Drug Dev. 2014;3(4):321–327. doi: 10.1002/cpdd.123
   PubMed Web of Science ®Google Scholar
• Ashton V, Mudarris L, Moore KT. The pharmacology, efficacy, and safety of rivaroxaban in obese patient populations. Am J Cardiovasc Drugs. 2021;21(3):283–297. doi: 10.1007/s40256-020-00434-w
   PubMed Web of Science ®Google Scholar
• Kubitza D, Becka M, Zuehlsdorf M, et al. Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects. J Clin Pharmacol. 2007;47(2):218–226. doi: 10.1177/0091270006296058
   PubMed Web of Science ®Google Scholar
• Kubitza D, Becka M, Roth A, et al. The influence of age and gender on the pharmacokinetics and pharmacodynamics of rivaroxaban-an oral, direct factor Xa inhibitor. J Clin Pharmacol. 2013;53:249–255. doi: 10.1002/jcph.5
   PubMed Web of Science ®Google Scholar
• Mueck W, Kubitza D, Becka M. Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects. Br J Clin Pharmacol. 2013;76(3):455–466. doi: 10.1111/bcp.12075
   PubMed Web of Science ®Google Scholar
• Ngo LT, Yang S, Tran QT, et al. Effects of carbamazepine and phenytoin on pharmacokinetics and pharmacodynamics of rivaroxaban. Pharmaceutics. 2020;12(11):1040. doi: 10.3390/pharmaceutics12111040
   PubMed Web of Science ®Google Scholar
• Kubitza D, Roth A, Becka M, et al. Effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban, an oral, direct factor Xa inhibitor. Br J Clin Pharmacol. 2013;76(1):89–98. doi: 10.1111/bcp.12054
   PubMed Web of Science ®Google Scholar
• Qamar A, Vaduganathan M, Greenberger NJ, et al. Oral anticoagulation in patients with liver disease. J Am Coll Cardiol. 2018;71(19):2162–2175. doi: 10.1016/j.jacc.2018.03.023
   PubMed Web of Science ®Google Scholar
• Kubitza D, Becka M, Mueck W, et al. Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct factor Xa inhibitor. Br J Clin Pharmacol. 2010;70(5):703–712. doi: 10.1111/j.1365-2125.2010.03753.x
   PubMed Web of Science ®Google Scholar
• Ashton V, Kerolus‐Georgi S, Moore KT. The pharmacology, efficacy, and safety of rivaroxaban in renally impaired patient populations. J Clin Pharmacol. 2021;61(8):1010–1026. doi: 10.1002/jcph.1838
   PubMed Web of Science ®Google Scholar
• Moj D, Maas H, Schaeftlein A, et al. A comprehensive whole-body physiologically based pharmacokinetic model of dabigatran etexilate, dabigatran and dabigatran glucuronide in healthy adults and renally impaired patients. Clin Pharmacokinet. 2019;58(12):1577–1593. doi: 10.1007/s40262-019-00776-y
   PubMed Web of Science ®Google Scholar
• Grainger B, Holloway R, Merriman E, et al. Evidence of impaired dabigatran absorption following laparoscopic Roux‐en‐Y gastric bypass surgery: the Auckland regional experience (2011–2018). Br J Haematol. 2020;191: doi: 10.1111/bjh.17004
   PubMed Web of Science ®Google Scholar
• Stangier J, Clemens A. Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor. Clin App Thrombosis/Hemostasis. 2009;15:9S–16S. doi: 10.1177/1076029609343004
   PubMed Web of Science ®Google Scholar
• Stangier J, Eriksson BI, Dahl OE, et al. Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement. J Clin Pharmacol. 2005;45(5):555–565. doi: 10.1177/0091270005274550
   PubMed Web of Science ®Google Scholar
• Stangier J, Rathgen K, Stähle H, et al. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol. 2007;64(3):292–303. doi: 10.1111/j.1365-2125.2007.02899.x
   PubMed Web of Science ®Google Scholar
• Piran S, Traquair H, Chan N, et al. Peak plasma concentration of direct oral anticoagulants in obese patients weighing over 120 kilograms: a retrospective study. Res Pract Thromb Haemost. 2018;2(4):684–688. doi: 10.1002/rth2.12146
   PubMed Web of Science ®Google Scholar
• Jacobs M, Ezekowitz M, Nagarakanti R, et al. Body mass index from the RE-LY trial: further evidence of the obesity paradox. Eur Heart J. 2022;43(Supplement_2):43. doi: 10.1093/eurheartj/ehac544.629
   Google Scholar
• Coates J, Bitton E, Hendje A, et al. Clinical outcomes of dabigatran use in patients with non-valvular atrial fibrillation and weight >120 kg. Thromb Res. 2021;208:176–180. doi: 10.1016/j.thromres.2021.11.007
   PubMed Web of Science ®Google Scholar
• Steffel J, Collins R, Antz M, et al. 2021 European Heart rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. EP Europace. 2021;23:1612–1676. doi: 10.1093/europace/euab065
   PubMed Web of Science ®Google Scholar
• Blech S, Ebner T, Ludwig-Schwellinger E, et al. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in Humans. Drug Metab Dispos. 2008;36(2):386–399. doi: 10.1124/dmd.107.019083
   PubMed Web of Science ®Google Scholar
• Ebner T, Wagner K, Wienen W. Dabigatran acylglucuronide, the major human metabolite of dabigatran: In Vitro formation, stability, and pharmacological activity. Drug Metab Dispos. 2010;38(9):1567–1575. doi: 10.1124/dmd.110.033696
   PubMed Web of Science ®Google Scholar
• Stangier J, Stähle H, Rathgen K, et al. Pharmacokinetics and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor, are not affected by moderate hepatic impairment. J Clin Pharmacol. 2008;48(12):1411–1419. doi: 10.1177/0091270008324179
   PubMed Web of Science ®Google Scholar
• Stangier J, Rathgen K, Stähle H, et al. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate. Clin Pharmacokinet. 2010;49(4):259–268. doi: 10.2165/11318170-000000000-00000
   PubMed Web of Science ®Google Scholar
• Skripka A, Sychev D, Bochkov P, et al. Factors affecting trough plasma dabigatran concentrations in patients with atrial fibrillation and chronic kidney disease. High Blood Pressure Cardiovasc Prev. 2020;27(2):151–156. doi: 10.1007/s40292-020-00373-2
   PubMed Web of Science ®Google Scholar
• Medicines and Healthcare Products Regulatory Agency. Prescribing medicines in renal impairment: using the appropriate estimate of renal function to avoid the risk of adverse drug reactions [Internet]. 2019 [cited 2022 Dec 12]. Available from: https://www.gov.uk/drug-safety-update/prescribing-medicines-in-renal-impairment-using-the-appropriate-estimate-of-renal-function-to-avoid-the-risk-of-adverse-drug-reactions.
   Google Scholar
• MacCallum PK, Mathur R, Hull SA, et al. Patient safety and estimation of renal function in patients prescribed new oral anticoagulants for stroke prevention in atrial fibrillation: a cross-sectional study. BMJ Open. 2013;3(9):e003343. doi: 10.1136/bmjopen-2013-003343
   PubMed Web of Science ®Google Scholar
• NHS North West Coast Strategic Networks. Consensus statement on how to calculate the creatinine clearance (CrCl) which is necessary when assessing the dose of direct-acting oral anticoagulants (DOACs) [Internet]. 2018 [cited 2022 Dec 12]. Available from: https://www.england.nhs.uk/north/wp-content/uploads/sites/5/2019/01/consensus-statement-on-CrCl-calculation-for-DOACs-final.pdf.
   Google Scholar
• Fanikos J, Burnett AE, Mahan CE, et al. Renal function and direct oral anticoagulant treatment for venous thromboembolism. Am J Med. 2017;130(10):1137–1143. doi: 10.1016/j.amjmed.2017.06.004
   PubMed Web of Science ®Google Scholar
• Fanikos J, Burnett AE, Mahan CE, et al. Renal function considerations for stroke prevention in atrial fibrillation. Am J Med. 2017;130(9):1015–1023. doi: 10.1016/j.amjmed.2017.04.015
   PubMed Web of Science ®Google Scholar
• Schwartz JB. Potential Effect of Substituting Estimated Glomerular Filtration Rate for Estimated Creatinine Clearance for Dosing of Direct Oral Anticoagulants. J Am Geriatr Soc. 2016;64(10):1996–2002. doi: 10.1111/jgs.14288
   PubMed Web of Science ®Google Scholar
• Martin K, Beyer‐Westendorf J, Davidson BL, et al. Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH. J Thromb Haemost. 2016;14(6):1308–1313. doi: 10.1111/jth.13323
   PubMed Web of Science ®Google Scholar
• Harkness W, Pipitone O, Joss J, et al. Observed Apixaban Anti-Xa Levels in Obese Patients. Ann Pharmacother. 2022 [cited 2023 Sep 12];56(11):1215–1221. doi: 10.1177/10600280221077158
   Web of Science ®Google Scholar
• Martin KA, Lancki N, Li C, et al. DOAC compared with warfarin for VTE in patients with obesity: a retrospective cohort study conducted through the VENUS network. J Thromb Thrombolysis. 2023 [cited 2023 Sep 12];55(4):685–690. doi: 10.1007/s11239-023-02774-1
   PubMed Web of Science ®Google Scholar
• Barakat AF, Jain S, Masri A, et al. Outcomes of direct oral anticoagulants in atrial fibrillation patients across different body mass index categories. JACC Clin Electrophysiol. 2021;7(5):649–658. doi: 10.1016/j.jacep.2021.02.002
   PubMedGoogle Scholar